Clinical and Experimental Allergy

Papers
(The H4-Index of Clinical and Experimental Allergy is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Atopic sensitization in childhood depends on the type of green area around the home in infancy148
Are paediatric allergy services promoting or harming public health?80
Featured Cover59
Eosinophil‐derived neurotoxin reference values in asthma: The way forward51
Anthropological and sociological perspectives on food allergy48
Association between long‐term occupational exposure to PM10 and allergic diseases in subway workers45
Patients with piperacillin–tazobactam allergy labels tolerate other beta‐lactams39
Nutritional disorders prevalence among adults with immunoglobin E‐mediated food allergy38
Poor head growth and developmental delay in infants with eczema, food allergies and growth faltering37
Cochrane corner: Pulmonary rehabilitation for adults with asthma34
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super‐Response and Remission With Mepolizumab34
The Asian wasp Vespa velutina nigrithorax: Entomological and allergological characteristics32
Molecular profile of specific IgE to allergenic components in allergic adults using allergen nano‐bead array31
Comparison of evidence of treatment effects in randomized and nonrandomized studies on allergen immunotherapy31
Sputum microRNA‐screening reveals Prostaglandin EP3 receptor as selective target in allergen‐specific immunotherapy30
Recombinant T‐cell epitope conjugation: A new approach for Dermatophagoides hypoallergen design30
Cluster analysis of nasal cytokines during rhinovirus infection identifies different immunophenotypes in both children and adults with allergic asthma29
Nitric oxide products and aldehydes in exhaled breath condensate in children with asthma28
Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series27
Ara h 2105‐124‐Specific TH2A Cells Drive Peanut Allergy in DRB1*15:01 Individuals: A Detailed Epitope Analysis27
Type 2 immunity‐driven diseases: Towards a multidisciplinary approach27
Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders26
Global Modelling Links Maternal Hypertensive Disorders to Early Childhood Allergic Disease Burden25
British Society for Allergy and Immunology (BSACI) Abstracts of the 2023 UK Conference (5–7 October, Harrogate Convention Centre, Harrogate, UK)25
0.067451000213623